In breast cancer patients with nodal disease, neoadjuvant chemotherapy (NACT) could result in pathological complete resolution of these metastatic lymph nodes in about 40% of patients, with a higher reported rate of 60%‐70% in human epidermal growth factor receptor 2 (HER2) positive patients.1 This high rate of nodal downstaging has led to the consideration of sentinel lymph node biopsy (SLNB) to stage the axilla post‐NACT, hence avoiding an axillary lymph node dissection (ALND) and its complications, which include arm lymphedema,2 in patients who had responded well to chemotherapy. Here, ERBB2 is linked to breast cancer.